腎臟生物製造商市場規模、佔有率、成長分析（按生物標記、診斷技術、地區）- 產業預測，2025-2032 年

2023年腎臟生物製造商的全球市場規模預計為12.9億美元，從2024年的13.9億美元成長到2032年的24.9億美元，預測期間（2025-2032年）預計複合年成長率為7.6%。

由於對腎臟疾病精確診斷工具和客製化治療策略的需求不斷成長，全球腎臟生物標記市場正處於強勁成長軌道。生物標記是腎功能的重要指標，有助於早期發現和監測慢性腎臟病、急性腎損傷等疾病。由於人口老化以及糖尿病和高血壓等生活方式因素，腎臟疾病的盛行率不斷增加，進一步推動了這項需求。生物標記檢測的技術進步極大地提高了檢測的準確性和可靠性，促進了明智的臨床決策。然而，它面臨著腎臟疾病的複雜性、需要多種生物標記進行綜合評估、監管障礙以及需要標準化檢測通訊協定等挑戰，導致其在臨床實踐中的廣泛使用成為障礙。

目錄

介紹

• 研究目的
• 調查範圍
• 定義

調查方法

• 資訊採購
• 二手資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制因素和挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 價格分析

腎臟生物製造商市場規模：依生物標記分類

• 市場概況
• 功能性生物標記
  • 血清肌酸酐
  • 血清胱Cystatin C
  • 尿液白蛋白
• 上調蛋白質
  • 嗜中性白血球明膠酶相關脂質運載蛋白
  • 腎損傷分子1
  • 白細胞介素-18
• 其他

腎臟生物製造商市場規模：依診斷技術

• 市場概況
• 酵素免疫分析法測定法 (ELISA)
• 粒子增強免疫檢測(PETIA)
• 比色分析
• 化學冷光酵素免疫分析法(CLIA)
• 液相層析法質譜法 (LS-MS)

腎臟生物製造商市場規模：按最終用戶分類

• 市場概況
• 診斷實驗室
• 門診
• 研究中心
• 醫院

腎臟生物製造商市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東/非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭資訊

• 前5名企業對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分類的佔有率分析
• 收益與前一年同期比較（2022-2024）

主要企業簡介

• Abbott Laboratories
• BioPorto Diagnostics AS
• F. Hoffmann-La Roche AG
• Thermo Fisher Scientific Inc.
• SEKISUI MEDICAL CO., LTD.
• BioMerieux SA
• Sphingotec GmbH
• Randox Laboratories Ltd
• Siemens Healthineers AG
• Enzo Life Sciences, Inc.
• Beckman Coulter, Inc.（Danaher Corporation）
• Fujirebio Inc.
• Bio-Rad Laboratories, Inc.
• Nova Biomedical Corporation
• Sysmex Corporation
• ACON Laboratories, Inc.
• Gold Standard Diagnostics Corp.
• R&D Systems, Inc.（Bio-Techne Corporation）
• Dako（Agilent Technologies, Inc.）
• DiaSorin SpA

結論和建議

Global Renal Biomakers Market size was valued at USD 1.29 billion in 2023 and is poised to grow from USD 1.39 billion in 2024 to USD 2.49 billion by 2032, growing at a CAGR of 7.6% during the forecast period (2025-2032).

The global renal biomarkers market is on a robust growth trajectory, driven by an escalating demand for precise diagnostic tools and tailored treatment strategies for kidney diseases. As key indicators of renal function, these biomarkers enhance the early detection and monitoring of conditions such as chronic kidney disease and acute kidney injury. The rising prevalence of renal diseases, exacerbated by aging populations and lifestyle factors like diabetes and hypertension, propels this demand further. Technological advancements in biomarker detection have significantly improved test accuracy and reliability, facilitating informed clinical decision-making. However, the market faces challenges, including the complexities of renal conditions necessitating multiple biomarkers for comprehensive assessments, regulatory hurdles, and the need for standardized testing protocols, which can hinder widespread adoption in clinical settings.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Renal Biomakers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Renal Biomakers Market Segmental Analysis

Global Renal Biomakers Market is segmented on the basis of type, end-user, and region. By type, the market is segmented into functional biomarkers, up-regulated proteins, and other biomarker types. By end user, the market is segmented into hospitals, diagnostic laboratories, and other end users. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver of the Global Renal Biomakers Market

One of the primary factors propelling the Global Renal Biomarkers market is the rising prevalence of renal diseases, such as chronic kidney disease (CKD), acute kidney injury (AKI), and kidney failure. As the rates of these conditions continue to increase, there is a heightened need for renal biomarkers, which are essential for the early detection, precise diagnosis, and effective monitoring of kidney-related ailments. These biomarkers are instrumental in facilitating timely medical interventions and enhancing patient outcomes, thereby significantly driving market growth and reinforcing their critical importance in healthcare strategies aimed at managing renal health.

Restraints in the Global Renal Biomakers Market

The Global Renal Biomarkers market faces various restraints, particularly due to regulatory challenges. The intricate and continuously changing regulatory environment surrounding biomarkers poses hurdles in acquiring necessary approvals and adhering to stringent quality and safety standards. This process can be lengthy and demand significant resources, ultimately impeding market growth and stifling innovation within the industry. Navigating these complex regulatory pathways presents a significant barrier for companies striving to develop and commercialize renal biomarkers, potentially delaying their entry into the market and affecting overall advancements in renal healthcare solutions.

Market Trends of the Global Renal Biomakers Market

The Global Renal Biomarkers market is witnessing a significant trend towards the increasing adoption of personalized medicine, which is reshaping patient care in nephrology. Healthcare providers are increasingly leveraging renal biomarkers to create individualized treatment strategies that take into account each patient's unique characteristics and the progression of their disease. This personalized approach not only enhances the efficacy of targeted therapies but also helps improve overall patient outcomes, fostering a paradigm shift in renal disease management. As a result, the market is expected to expand rapidly, driven by innovations in biomarker research and the growing emphasis on customized healthcare solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Renal Biomakers Market Size by Biomarker & CAGR (2025-2032)

• Market Overview
• Functional Biomarker
  • Serum Creatinine
  • Serum Cystatin C
  • Urine Albumin
• Up-Regulated Proteins
  • Neutrophil Gelatinase-Associated Lipocalin
  • Kidney Injury Molecule-1
  • Interleukin-18
• Others

Global Renal Biomakers Market Size by Diagnostic Technique & CAGR (2025-2032)

• Market Overview
• Enzyme Linked Immunosorbent Assay (ELISA)
• Particle-Enhanced Turbidimetric Immunoassay (PETIA)
• Colorimetric Assay
• Chemiluminescent Enzyme Immunoassay (CLIA)
• Liquid Chromatography-Mass Spectrometry (LS-MS)

Global Renal Biomakers Market Size by End User & CAGR (2025-2032)

• Market Overview
• Diagnostic Labs
• Outpatient Clinics
• Research Centers
• Hospitals

Global Renal Biomakers Market Size & CAGR (2025-2032)

• North America (Biomarker, Diagnostic Technique, End User)
  • US
  • Canada
• Europe (Biomarker, Diagnostic Technique, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Biomarker, Diagnostic Technique, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Biomarker, Diagnostic Technique, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Biomarker, Diagnostic Technique, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
• Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioPorto Diagnostics AS
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SEKISUI MEDICAL CO., LTD.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMerieux SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sphingotec GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Randox Laboratories Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Enzo Life Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beckman Coulter, Inc. (Danaher Corporation)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujirebio Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nova Biomedical Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ACON Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gold Standard Diagnostics Corp.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• R&D Systems, Inc. (Bio-Techne Corporation)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dako (Agilent Technologies, Inc.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DiaSorin S.p.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations